IIT study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"

The IIT (Investigator Initiated Trial) study CLEAR "Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)" should take place in 26 trial sites in Germany and 4 trial sites in Italy. The University of Münster acts as sponsor of the clinical trial CLEAR according to Article 2 No. 14 Regulation (EU) 536/2014 (CTR). For the conduct of the study in Italy, we would like to transfer the following tasks in the areas of project management, trial start-up, monitoring and quality assurance to another institution in Italy. A synopsis of the study is attached to this tender as Appendix 1. A framework agreement will be concluded afterwards.